Melanoma, Cutaneous Malignant clinical trials
The registry lists 17 studies for Melanoma, Cutaneous Malignant across more than 10 countries. 5 are recruiting or about to start. 9 of them are mainly about Melanoma, Cutaneous Malignant (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its narrower condition Dysplastic Nevus Syndrome too: 41 studies, 12 open.
Get an email when these change. Save the Melanoma, Cutaneous Malignant studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Immuneering Corporation (2) · Icahn School of Medicine at Mount Sinai (1) · Universitaire Ziekenhuizen KU Leuven (1) · University of Arkansas (1) · Prof. Dr. med. Dirk Schadendorf (1) · Immatics US, Inc. (1) · Case Comprehensive Cancer Center (1) · National Cancer Institute (NCI) (1)
What is being tested here
Drugs under test in Melanoma, Cutaneous Malignant studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Anzutresgene autoleucel | 1 | 1 | 1 |
| Vitamin D | 0 | 1 | 1 |
| Nintedanib | 0 | 0 | 1 |
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The study
- Jun 2027A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors · Immuneering Corporation
Who these studies take
Of the 3 Melanoma, Cutaneous Malignant studies recruiting now, 3 (100%) set no upper age limit and 0 (0%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 3 (100%) | 3 (100%) |
| 30 | 3 (100%) | 3 (100%) |
| 40 | 3 (100%) | 3 (100%) |
| 50 | 3 (100%) | 3 (100%) |
| 65 | 3 (100%) | 3 (100%) |
| 75 | 3 (100%) | 3 (100%) |
| 85 | 3 (100%) | 3 (100%) |
Across all 17 studies, recruiting or not: 0% stop at 75 or younger and 0% at 65; 24% take children; 0% are for women only and 0% for men only; 12% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 17 of 17. search them.
- Clinical Genetics Branch Eligibility Screening SurveyNot yet recruitingNCT070052971 country
- SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous MelanomaRecruitingNCT06743126Phase 36 countries
- Electrochemotherapy Changes in Tumor Microenvironment of Cutaneous and Subcutaneous Metastases in Melanoma PatientsEnrolling by invitationNCT06388252Not applicable1 country
- Pancreas Registry and High Risk RegistryRecruitingNCT027754611 country
- EMDR for Fear of Cancer Recurrence in Patients with Familial Melanoma: a Waiting List Control TrialRecruitingNCT06767332Not applicable1 country
- Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid TumorsCompletedNCT05479812Phase 11 country
- A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid TumorsActive, not recruitingNCT05585320Phase 1/21 country
- Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in CancerActive, not recruitingNCT04620603Phase 11 country
- A Study of IMM-6-415 in RAS/RAF Mutant Solid TumorsCompletedNCT06208124Phase 1/21 country
- Vitamin D Supplementation in Cutaneous Malignant Melanoma OutcomeCompletedNCT01748448Phase 32 countries
- Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic MelanomaCompletedNCT02308553Phase 1/21 country
- Pancreatic Cancer Screening of High-Risk Individuals in ArkansasWithdrawnNCT02309632Not applicable1 country
- Evaluation of Oncoxin-Viusid® in Cutaneous MelanomaCompletedNCT03541148Phase 21 country
- Genetic Analysis of Familial MelanomaCompletedNCT003394041 country
- Tailored Intervention for Melanoma Patient's FamiliesCompletedNCT00816374Not applicable1 country
- Identifying Gene Mutations in Patients With Melanoma and in Families With a History of Hereditary MelanomaStatus unknownNCT004505931 country
- Comparative Microarray Analysis in Primary Cutaneous Malignant MelanomaCompletedNCT014822601 country